Gilead Sciences Stock News

Company sees strong growth in VEKLURY sales, driven by increased Covid-19 hospitalizations, with Q3 2024 sales up 9% to $692 million. LIVDELZI shows promise for long-term growth, with FDA Accelerated Approval for PBC and potential EMA approval in Q1 2025. TRODELVY sales increased by 17% year-over-year, with potential expansion into ES-SCLC and other Trop-2 expressing solid tumors.

Trump has pledged to protect Social Security and Medicare throughout his campaign, one analyst noted, but this was the first time he added Medicaid to the list.

Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value TEANECK, N.J. , Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as it advances innovations to prevent and t...

For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid tr...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.

Gilead Sciences, Inc. (NASDAQ:GILD ) JPMorgan Annual Healthcare Conference Call January 13, 2025 2:15 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Stacey Ma - Executive Vice President, Pharmaceutical Development and Manufacturing Andrew Dickinson - Chief Financial Officer Flavius Martin - Executive Vice President, Rese...

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O'Day. He dubbed lenacapavir – the company's twice-a-year HIV shot a “once-in-a-decade medicine” in an interview with CNBC today as it was found to be 100% effective in a late-stage trial.